Search Videos and More
Video
FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD
Dana-Farber Cancer Institute's Dr. Pasi Jänne details FLAURA2 which found first-line osimertinib + platinum pemetrexed chemotherapy improved overall survival vs. monotherapy in EGFR mutated non-small cell lung cancer, including poorer prognosis patients.
Video
ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
Video
Head and Neck Study Presented by Robert Haddad, MD
Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.
Video
Paolo Tarantino, MD, PhD, on ADCs
The Next Frontier of Antibody-Drug Conjugate Development - Dana-Farber's Paolo Tarantino, MD, discussed how to optimize the safety of antibody drug conjugates at a session during ESMO25.
News
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Jessica St. Laurent, MD, was sure something had gone wrong. The results of an experiment she’d run showed that the cancer cells she was studying had abnormally high levels of a specific collection of proteins of interest to her team.
News
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.
News
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.
News
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.
News
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.
News
Dana-Farber Research News 10.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 - September 30.
Course
Dana-Farber Center for BRCA & Related Genes Scientific Symposium
Explore the latest advances in hereditary cancer research and care at the Dana-Farber Center for BRCA and Related Genes Scientific Symposium, designed for clinicians and researchers to deepen knowledge of detection, treatment, and ethical issues in BRCA-associated cancers across multiple tumor types.
News
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.